Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 11/20 | 0.38 |
| ▸ | AKT1 | P31749 | 10/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2062816 | 0.99 | APP (0.39) | APPP2RY14RPS6KB1AKT1TLR9 | |
| SCHEMBL4239895 | 0.89 | P2RY14 (0.41) | APPP2RY14RPS6KB1AKT1TLR9 | |
| Hydrochloric Acid SCHEMBL311632 | 0.88 | P2RY14 (0.41) | APPP2RY14RPS6KB1AKT1TLR9 | |
| SCHEMBL14782372 | 0.80 | RPS6KB1 (0.50) | APPP2RY14RPS6KB1AKT1RPS6KA3 | |
| SCHEMBL27796918 | 0.79 | SOS1 (0.45) | RPS6KB1AKT1SOS1 | |
| Hydrochloric Acid SCHEMBL15732670 | 0.78 | SOS1 (0.45) | RPS6KB1AKT1SOS1 | |
| SCHEMBL15720535 | 0.77 | RPS6KB1 (0.52) | RPS6KB1AKT1 | |
| Hydrochloric Acid SCHEMBL11904761 | 0.77 | RPS6KB1 (0.51) | RPS6KB1AKT1 | |
| SCHEMBL16987135 | 0.76 | AKT1 (0.47) | RPS6KB1AKT1SOS1 | |
| Hydrochloric Acid SCHEMBL11904264 | 0.73 | RPS6KB1 (0.44) | RPS6KB1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358710-B1 | AKT AND P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8148387-B2 | AKT and P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, MTOR | APP 3548/4885P2RY14 2781/4885RPS6KB1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.